Emmert, M Y; Salzberg, S P; Emmert, L S; Behjati, S; Plass, A; Felix, C; Falk, V; Grünenfelder, J (2009). Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease. European Journal of Heart Failure, 11(11):1106-1109.
Full text not available from this repository.
Adalimumab belongs to the group of tumour necrosis factor-alpha inhibitors and has been approved for the treatment Crohn's Disease since 2007. Herein we report a severe adverse reaction to adalimumab in a 25-year-old female patient. One week after the initial-dose of adalimumab (160 mg), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a fulminant cardiomyopathy. In severe cardiogenic shock, the patient required an extracorporeal membrane-oxygenation system for 8 days until cardiac recovery.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiovascular Surgery|
04 Faculty of Medicine > University Hospital Zurich > Institute of Anesthesiology
|DDC:||610 Medicine & health|
|Deposited On:||02 Feb 2010 17:45|
|Last Modified:||27 Nov 2013 23:19|
|Citations:||Web of Science®. Times Cited: 4|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page